Aether Industries Ltd
Aether Industries Ltd
ChemicalsKey Fundamentals
SmallcapSpecialty ChemicalsChemicalsInsights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Aether Industries Ltd insights
49 extracted metrics + investor summaries across FY13–FY26.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Strengths
1- Company is expected to give good quarter
Weaknesses
3- Stock is trading at 8.68 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 7.91% over last 3 years.
Growth Rate
AI Analysis — Bull vs Bear
Aether Industries is a specialty chemicals company trading at a PE of 89.2x and 8.54x book value with a market cap of ₹21,513 crore. FY25 consolidated revenue grew ~38-40% YoY to ~₹8,400-8,800 crore million range while PAT grew ~92% YoY, reflecting a strong recovery from a weak FY24, though 3-year average ROE remains modest at ~8%.
- FY25 consolidated revenue grew ~38-40% YoY to ₹8,387-8,803 million, demonstrating strong top-line momentum after a subdued FY24
- FY25 PAT surged ~92% YoY to ₹1,584 million, showing significant operating leverage as capacity utilisation improved
- Q4 FY25 revenue of ₹2,453 million was up 90% YoY with EBITDA margins expanding sharply — EBITDA at ₹819 million (+469% YoY)
- FY26 revenue reached ₹11,601 million (+38% YoY over FY25), indicating sustained growth trajectory beyond a one-time recovery
- TTM sales CAGR of 34% and profit CAGR of 30% indicate above-average growth for the specialty chemicals sector
- Stock has delivered 119% returns over 1 year and 16% CAGR over 3 years, reflecting improving market confidence in the business model
- Aggressive capex of ₹3,838 million in FY26 with ₹3,000-3,500 million planned for FY27 (Site 5 and new R&D) positions the company for future revenue scale-up
- Low debt-to-equity ratio of ~9.2% provides financial flexibility to fund growth without significant balance sheet stress
- PE ratio of 89.2x is expensive even by specialty chemicals standards, leaving little room for execution misses
- 3-year average ROE of just 7.91-8% is low for a company valued at 8.54x book value, indicating poor capital efficiency relative to valuation
- Zero dividend yield despite consistent profitability — company retains all earnings but ROE has not meaningfully expanded
- Stock trades at 8.78x book value, implying market expects significantly higher returns on equity than the company currently delivers
- Q4 FY24 reported a net loss of ₹1.43 crore vs profit of ₹37.56 crore YoY, highlighting earnings volatility and customer concentration risks
- 5-year and 10-year ROE data unavailable, and last year ROE at 10% is still modest for the premium valuation commanded
- Heavy ongoing capex (₹3,000-3,500 million annually) will suppress free cash flow and may dilute returns if revenue ramp-up from new sites is delayed
- FY24 full-year revenue declined to ₹5,995 million from ₹6,544 million in FY23, showing the business can contract meaningfully in down-cycles
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
- Strong Q1 revenue and profit growth Aug 7
Aether Industries reported 27% revenue growth to ₹3,266 crore in Q1FY27 with net profit rising 33% to ₹627 crore.
- Exclusive R&D tie-up with Dow Jul 31
Aether and Dow Chemical launched a joint research program for indigenous silicone manufacturing technologies in India, with pilot development at Aether's Surat facility.
- Investor meet in Singapore Aug 10
Aether will participate in the Ambit-Daiwa India Access conference in Singapore on August 17-18, 2026. No UPSI will be discussed.
- Q1 earnings call scheduled Jul 27
Aether held an earnings conference call on July 31, 2026 at 15:30 IST conducted by HDFC Securities to discuss June quarter results.
TL;DR: Aether Industries is firing on both growth and strategic fronts, delivering 27-33% topline and bottomline growth in Q1FY27 while securing a landmark Dow Chemical partnership in silicones. No visible headwinds in the current news cycle. The trend is clearly improving with strong earnings momentum and a high-value R&D collaboration that could open a new growth vertical.
Quarterly Results
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 161 | 164 | 155 | 118 | 180 | 199 | 220 | 240 | 257 | 280 | 319 | 305 | 327 |
| Expenses | 116 | 118 | 124 | 107 | 137 | 145 | 155 | 161 | 175 | 192 | 207 | 222 | 224 |
| Operating Profit | 45 | 46 | 31 | 10 | 43 | 54 | 65 | 80 | 81 | 88 | 112 | 83 | 103 |
| OPM % | 28% | 28% | 20% | 9% | 24% | 27% | 29% | 33% | 32% | 31% | 35% | 27% | 31% |
| Other Income | 2 | 14 | 5 | 4 | 9 | 8 | 11 | 2 | -1 | 6 | -4 | 10 | 8 |
| Interest | 1 | 2 | 2 | 4 | 3 | 2 | 3 | 5 | 5 | 3 | 4 | 6 | 6 |
| Depreciation | 9 | 10 | 10 | 10 | 10 | 11 | 11 | 13 | 14 | 17 | 17 | 18 | 21 |
| PBT | 37 | 49 | 24 | 0 | 39 | 49 | 61 | 64 | 62 | 74 | 87 | 68 | 83 |
| Tax % | 19% | 25% | 27% | 486% | 24% | 28% | 29% | 21% | 24% | 27% | 26% | 21% | 25% |
| Net Profit | 30 | 37 | 17 | -1 | 30 | 35 | 43 | 50 | 47 | 54 | 64 | 54 | 63 |
| EPS in Rs | 2.25 | 2.77 | 1.31 | -0.11 | 2.26 | 2.63 | 3.27 | 3.79 | 3.55 | 4.07 | 4.86 | 4.07 | 4.73 |
Profit & Loss
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|
| Sales | 590 | 651 | 598 | 839 | 1,160 | 1,231 |
| Expenses | 422 | 465 | 466 | 598 | 796 | 845 |
| Operating Profit | 168 | 186 | 132 | 241 | 364 | 386 |
| OPM % | 28% | 29% | 22% | 29% | 31% | 31% |
| Other Income | 7 | 17 | 25 | 30 | 12 | 20 |
| Interest | 13 | 5 | 9 | 13 | 18 | 19 |
| Depreciation | 15 | 23 | 40 | 45 | 66 | 74 |
| PBT | 146 | 174 | 110 | 213 | 291 | 313 |
| Tax % | 26% | 25% | 25% | 26% | 25% | — |
| Net Profit | 109 | 130 | 82 | 158 | 219 | 235 |
| EPS in Rs | 9.67 | 10.47 | 6.22 | 11.95 | 16.54 | 17.73 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 113 | 125 | 133 | 133 | 133 |
| Reserves | 274 | 1,120 | 1,931 | 2,093 | 2,323 |
| Borrowings | 291 | 16 | 183 | 200 | 458 |
| Other Liabilities | 92 | 120 | 154 | 218 | 288 |
| Total Liabilities | 770 | 1,380 | 2,401 | 2,644 | 3,201 |
| Fixed Assets | 257 | 646 | 853 | 1,117 | 1,506 |
| CWIP | 58 | 37 | 232 | 363 | 506 |
| Investments | 17 | 1 | 0 | 0 | 0 |
| Other Assets | 438 | 695 | 1,315 | 1,163 | 1,189 |
| Total Assets | 770 | 1,380 | 2,401 | 2,644 | 3,201 |
Cash Flow
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Operating | -5 | -7 | -16 | 100 | 142 |
| Investing | -151 | -348 | -424 | -418 | -619 |
| Financing | 169 | 439 | 894 | 2 | 244 |
| Net Cash Flow | 12 | 84 | 453 | -316 | -233 |
| Free Cash Flow | -157 | -363 | -444 | -352 | -390 |
| CFO/OP | 17 | 14 | 1 | 57 | 54 |
Ratios
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor Days | 101 | 145 | 142 | 126 | 123 |
| Inventory Days | 221 | 301 | 411 | 356 | 326 |
| Days Payable | 95 | 99 | 124 | 114 | 120 |
| Cash Conversion Cycle | 227 | 348 | 429 | 367 | 330 |
| Working Capital Days | 82 | 268 | 279 | 238 | 160 |
| ROCE % | — | 18% | 7% | 10% | 12% |
Documents
Frequently Asked Questions about Aether Industries Ltd
What does Aether Industries Ltd do?
Where is Aether Industries Ltd (AETHER) listed?
Which sector does Aether Industries Ltd belong to?
What is the market capitalisation of Aether Industries Ltd?
What is the PE ratio of Aether Industries Ltd?
What is the 52-week high and low of Aether Industries Ltd?
What is the Return on Equity (ROE) of Aether Industries Ltd?
How can I research Aether Industries Ltd on Tapetide?
Company Information
Incorporated in 2013, Aether Industries Limited is a manufacturer of specialty chemicals. The company is sole Indian manufacturer for chemicals such as 4-(2-Methoxyethyl) Phenol (4MEP), and 3-Methoxy-2-Methylbenzoyl Chloride (MMBC), Thiophene-2-Ethanol (T2E), Ortho Tolyl Benzo Nitrile (OTBN), N-Octyl-D-Glucamine, Delta-Valerolactone, and Bifenthrin Alcohol.[1]